Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP

作者：Kobayashi Yujin^*; Hatta Yoshihiro; Hojo Atsuko; Kura Yoshimasa; Uchino Yoshihito; Takahashi Hiromichi; Kiso Satomi; Hirabayashi Yukio; Yagi Mai; Kodaira Hitomi; Kurita Daisuke; Tanaka Toshitake; Miura Katsuhiro; Iriyama Noriyoshi; Kobayashi Sumiko; Sawada Umihiko; Sugitani Masahiko; Takeuchi Jin

来源：Experimental and Therapeutic Medicine, 2012, 3(2): 304-308.

DOI：10.3892/etm.2011.387

• primary gastric diffuse large B-cell lymphoma
• relative dose intensity
• Helicobacter pylori
• R-CHOP

The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP(i.e.,R-CHOP)] is considered to be the standard regimen for treating localized, primary gastric diffuse large B-cell lymphoma (PG-DLBCL). However, few studies have reported the long-term efficacy of R-CHOP therapy in the management of localized PG-DLBCL. In the present study, we performed a retrospective analysis of 11 patients with localized PG-DLBCL, who were treated with R-CHOP at Nihon University Itabashi Hospital and Kasukabe Municipal Hospital (Japan) from 2001 to 2008. Limited stage cancer was defined as stage I/II according to the Lugano staging system for gastrointestinal (GI) lymphomas. The relative dose intensity (RDI) of CHOP therapy was calculated for each patient. The median age of the patients was 68 years (range, 48-82). Gastralgia and anemia were common symptoms at initial presentation. All patients except I received 6 cycles of R-CHOP treatment without consolidative radiation therapy or prior surgery. RDI was maintained at over 80% in 9 out of 11 patients. All patients achieved complete remission and the estimated overall survival with a median follow-up of 54 months (range, 39-103) was 100%, without relapse or significant GI adverse effects, such as perforation or bleeding during R-CHOP treatment. No long-term adverse effects of rituximab were recorded during the observation period. Helicobacter pylori infection was diagnosed in 72.7% (8 cases) of the patients, but was eradicated in a limited number of patients. Our data suggest the feasibility and effectiveness of the addition of rituximab to conventional CHOP therapy in the management of localized PG-DLBCL.

• 出版日期2012-2